LONG BEACH, Calif. / Aug 20, 2024 / Business Wire / Molina Healthcare, Inc. (NYSE: MOH) (“Molina” or the “Company”) announced today that its Board of Directors has entered into a contract amendment with President and Chief Executive Officer, Joe Zubretsky, designed to secure Mr. Zubretsky’s tenure through at least the end of 2027. Zubretsky, 67, joined Molina as President and Chief Executive Officer in November of 2017.
“Under Joe’s leadership we have the right strategy, great execution, and have created significant value for shareholders,” said Dale Wolf, Molina’s Chairman of the Board. “We are delighted that Joe will be at the helm for the foreseeable future to continue to do so.”
Under this contract amendment, Zubretsky was awarded a special one-time stock grant that will vest at the end of 2027 contingent upon the achievement of certain financial targets. His annual compensation remains unchanged.
About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit MolinaHealthcare.com.
| Last Trade: | US$332.38 |
| Daily Change: | -3.12 -0.93 |
| Daily Volume: | 1,144,828 |
| Market Cap: | US$19.010B |
November 18, 2024 October 23, 2024 October 16, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
